Krish Patel, MD, Swedish Medical Center

home / authors / krish-patel-md-swedish-medical-center

Articles

Next Steps in Mantle Cell Lymphoma

Next Steps in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
March 2nd 2021

Read More

MRD Assessment in Mantle Cell Lymphoma

MRD Assessment in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
March 2nd 2021

Read More

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
March 2nd 2021

Read More

MCL: Emerging BTKi-Combination Approaches

MCL: Emerging BTKi-Combination Approaches

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 23rd 2021

Read More

Emerging BTK Inhibitors in Mantle Cell Lymphoma

Emerging BTK Inhibitors in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 23rd 2021

Read More

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 16th 2021

Read More

Venetoclax in Mantle Cell Lymphoma

Venetoclax in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 16th 2021

Read More

BTK Inhibitors for Relapsed MCL: Important Considerations

BTK Inhibitors for Relapsed MCL: Important Considerations

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 9th 2021

Read More

Selecting a BTKi for Relapsed MCL Treatment

Selecting a BTKi for Relapsed MCL Treatment

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 9th 2021

Read More

Acalabrutinib and Zanubrutinib for Relapsed MCL

Acalabrutinib and Zanubrutinib for Relapsed MCL

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 2nd 2021

Read More

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
February 2nd 2021

Read More

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 26th 2021

Read More

Go-To Treatment Regimens in Mantle Cell Lymphoma

Go-To Treatment Regimens in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 26th 2021

Read More

Treatment Approaches in Mantle Cell Lymphoma

Treatment Approaches in Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 19th 2021

Read More

Accurately Diagnosing Mantle Cell Lymphoma

Accurately Diagnosing Mantle Cell Lymphoma

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine;Krish Patel, MD, Swedish Medical Center;Tycel Jovelle Phillips, MD, University of Michigan;Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
January 19th 2021

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data